DENISE SIQUEIRA VANNI
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Synbiotic Supplementation Modulates Gut Microbiota, Regulates beta-Catenin Expression and Prevents Weight Gain in ob/ob Mice: Preliminary Findings(2022) DUARTE, Sebastiao Mauro B.; STEFANO, Jose Tadeu; FRANCO, Lucas A. M.; MARTINS, Roberta C.; MORAES, Bruna D. G. C.; BARBEIRO, Denise Frediani; OLIVEIRA, Nathalia; NERI, Junia Marielle Teixeira Rodrigues; COGLIATI, Bruno; VANNI, Denise Siqueira; SABINO, Ester C.; CARRILHO, Flair J.; OLIVEIRA, Claudia P.Background: Obesity is one of the main health problems in the world today, and dysbiosis seems to be one of the factors involved. The aim of this study was to examine the impact of synbiotic supplementation on obesity and the microbiota in ob/ob mice. Twenty animals were divided into four groups: obese treated (OT), obese control (OC), lean treated (LT) and lean control (LC). All animals received a standard diet for 8 weeks. The treated groups received a synbiotic (Simbioflora-Invictus Farmanutricao Ltd., Sao Paulo, Brazil) in water, while the nontreated groups received only water. After 8 weeks, all animals were sacrificed, and gut tissue and stool samples were collected for mRNA isolation and microbiota analysis, respectively. beta-Catenin, occludin, cadherin and zonulin in the gut tissue were analyzed via RT-qPCR. Microbiome DNA was extracted from stool samples and sequenced using an Ion PGM Torrent platform. Results: Synbiotic supplementation reduced body weight gain in the OT group compared with the OC group (p = 0.0398) and was associated with an increase in Enterobacteriaceae (p = 0.005) and a decrease in Cyanobacteria (p = 0.047), Clostridiaceae (p = 0.026), Turicibacterales (p = 0.005) and Coprococcus (p = 0.047). On the other hand, a significant reduction in Sutterella (p = 0.009) and Turicibacter (p = 0.005) bacteria was observed in the LT group compared to the LC group. Alpha and beta diversities were different among all treated groups. beta-Catenin gene expression was significantly decreased in the gut tissue of the OT group (p <= 0.0001) compared to the other groups. No changes were observed in occludin, cadherin or zonulin gene expression in the gut tissue. Conclusions: Synbiotic supplementation prevents excessive weight gain, modulates the gut microbiota, and reduces beta-catenin expression in ob/ob mice.
- Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease(2021) STEFANO, Jose Tadeu; GUEDES, Laura Vilar; SOUZA, Arthur Alencar Arrais de; VANNI, Denise Siqueira; ALVES, Venancio Avancini Ferreira; CARRILHO, Flair Jose; LARGURA, Alvaro; ARRESE, Marco; OLIVEIRA, Claudia P.Introduction/aims: Liver fibrosis assessment is a key issue in the evaluation of nonalcoholic fatty liver disease (NAFLD) patients. In the present study, we aimed to validate a noninvasive marker panel to assess significant and advanced fibrosis in these patients. Method: 126 biopsy-proven NAFLD patients were included. NAFLD diagnosis was based on histological criteria. Fibrosis stages were determined according to NASH-Clinical Research Network criteria. Clinical and laboratorial data were collected during the interval of three months before or after liver biopsy. Histological fibrosis stages were classified as significant fibrosis (F2-F4) and advanced fibrosis (F3-F4). Five serum biomarkers [hyaluronic acid (HA), collagen type IV (cIV), procollagen type III (PC III), laminin (LN) and cholylglycine (CG)] were assessed by chemiluminescence immunoassays. Results: Most patients were female (61.61%), mean age: 55.7 +/- 9.13 years old and mean BMI was 32.1 +/- 5.9 kg/m(2). Prevalence of diabetes, dyslipidemia, arterial hypertension, and metabolic syndrome was 68.75%, 82.29%, 63.54% and 81.05%, respectively. Patients with cIV above 30 ng/mL had a 5.57-times (IC: 1.86-16.69) the chance of having significant fibrosis and 7.61-times (IC: 2.27-25.54) the chance of having advanced fibrosis versus patients with values below 30 ng/mL. HA, PC III, LN and CG did not detect the presence of significant and advanced fibrosis. The AUROC of clV for detection of significant (0.718) and advanced fibrosis (0.791) was better than that of other serum biomarkers. Conclusion: Type 4 collagen could predict the presence of significant and advanced fibrosis in NAFLD patients and it would be a useful tool in routine clinical practice. (C) 2020 Fundacion Clinica Medica Sur, A.C.
conferenceObject Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population(2020) ZAMBRANO-HUAILLA, Rommel; GUEDES, Laura; SOUZA, Arthur A. Arrais de; STEFANO, Jose Tadeu; MARCIANO, Sebastian; YVAMOTO, Erika; MICHALCZUK, Matheus Truccolo; VANNI, Denise Siqueira; RODRIGUEZ, Hernan; CARRILHO, Flair Jose; ALVARES-DA-SILVA, Mario Reis; ARRESE, Marco; GADANO, Adrian; MIRANDA, Adelina Lozano; OLIVEIRA, Claudia- Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population(2020) ZAMBRANO-HUAILLA, Rommel; GUEDES, Laura; STEFANO, Jose Tadeu; SOUZA, Arthur A. Arrais de; MARCIANO, Sebastian; YVAMOTO, Erika; MICHALCZUK, Matheus Truccolo; VANNI, Denise Siqueira; RODRIGUEZ, Hernan; CARRILHO, Flair Jose; ALVARES-DA-SILVA, Mario Reis; GADANO, Adrian; ARRESE, Marco; MIRANDA, Adelina Lozano; OLIVEIRA, Claudia P.Introduction and aims: Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods: Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results: The distribution of fibrosis stages among the sample population was as follows: F0 (45%), Fl (27%), F2 (8%), F3 (16%) and F4 (4%). Using modified thresholds, the areas under the ROC curves (AUROC) for Hepamet and FIB-4 (0.73 and 0.74, respectively) to detect significant fibrosis were higher than that of NFS (0.58). However, the AUROCs of the three scores were not significantly different in advanced fibrosis and cirrhosis. To exclude fibrosis, we calculated lower cutoffs than standard thresholds for Hepamet, FIB-4 and NFS with similar performances. Conclusion: Thresholds of non-invasive fibrosis scores (Hepamet, FIB-4 and NFS) can be modified to maximize diagnostic accuracy in Latin American patients with NAFLD. (C) 2020 Fundacion Clinica Medica Sur, A.C.
conferenceObject NADPH OXIDASE (NOX 4) AND P22PHOX GENE POLYMORPHISMS ARE ASSOCIATED WITH HUMAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)(2014) RABELO, F.; STEFANO, J. T.; LIMA, R. V.; SEIXAS, M.; PATENTE, T.; VANNI, D.; CAVALEIRO, A. M.; MAZO, D. C.; CARRILHO, F. J.; CORREA-GIANNELLA, M. L.; OLIVEIRA, C.conferenceObject Comparison between Results of Hepatic Transient Elastography (fibroscan (R)) and Controlled Attenuation Parameter (cap (TM)) versus Liver Biopsy in NAFLD Patients(2013) VANNI, Denise S.; OLIVEIRA, Claudia P.; MAZO, Daniel F.; RABELO, Fabiola; STEFANO, Jose Tadeu; CARRILHO, Flair J.- IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)(2019) DUARTE, Sebastião Mauro Bezerra; STEFANO, José Tadeu; VANNI, Denise Siqueira; CARRILHO, Flair José; OLIVEIRA, Claudia Pinto Marques Souza deABSTRACT The nonalcoholic fatty liver disease (NAFLD) affects approximately 20%-30% of general population and is even more prevalent among obese individuals. The risk factors mainly associated with NAFLD are diseases related to the metabolic syndrome, genetics and environment. In this review, we provide a literature compilation evaluating the evidence behind dietary components, including calories intake, fat, protein, fibers and carbohydrate, especially fructose which could be a trigger to development and progression of the NAFLD. In fact, it has been demonstrated that diet is an important factor for the development of NAFLD and its association is complex and extends beyond total energy intake.